GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

Home・Aandelen Lijst・Novo Nordisk A-S (Class B)
Search

Novo Nordisk A-S (Class B)

Gesloten

300.1 1.18

Buy

Prijsupdate 13 mei 2026, 14:54 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

299.85

Max

301.75

Belangrijke statistieken

By Trading Economics

Inkomsten

22B

49B

Verkoop

18B

97B

K/W

Sectorgemiddelde

11.012

51.415

EPS

10.91

Dividendrendement

3.9

Winstmarge

50.15

Werknemers

67,900

EBITDA

32B

69B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.53% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.90%

2.34%

Volgende Winsten

5 aug 2026

Volgende Ex Dividend datum

13 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

84B

1.3T

Vorige openingsprijs

298.92

Vorige sluitingsprijs

300.1

Novo Nordisk A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mei 2026, 15:48 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

DJ

Lezen

6 mei 2026, 07:30 UTC

Winsten

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

DJ

Lezen

6 mei 2026, 06:19 UTC

Winsten

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

DJ

Lezen

12 mei 2026, 12:05 UTC

Populaire aandelen

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

DJ

Lezen

12 mei 2026, 10:51 UTC

Populaire aandelen

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

DJ

Lezen

12 mei 2026, 09:42 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

DJ

Lezen

12 mei 2026, 09:08 UTC

Populaire aandelen

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

DJ

Lezen

11 mei 2026, 20:30 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

DJ

Lezen

7 mei 2026, 09:30 UTC

Winsten

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

DJ

Lezen

6 mei 2026, 12:36 UTC

Winsten

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

DJ

Lezen

6 mei 2026, 10:53 UTC

Populaire aandelen

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

DJ

Lezen

6 mei 2026, 10:12 UTC

Winsten

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

DJ

Lezen

6 mei 2026, 09:58 UTC

Winsten

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

DJ

Lezen

6 mei 2026, 09:35 UTC

Populaire aandelen

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

DJ

Lezen

6 mei 2026, 08:13 UTC

Marktinformatie
Winsten

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

DJ

Lezen

6 mei 2026, 07:43 UTC

Marktinformatie
Winsten

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

DJ

Lezen

6 mei 2026, 07:00 UTC

Winsten

Novo Nordisk Shares Rise 5.5% After 1Q Results

DJ

Lezen

6 mei 2026, 06:34 UTC

Winsten

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

DJ

Lezen

6 mei 2026, 06:26 UTC

Winsten

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

DJ

Lezen

6 mei 2026, 06:26 UTC

Winsten

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

DJ

Lezen

6 mei 2026, 06:24 UTC

Winsten

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

DJ

Lezen

6 mei 2026, 06:20 UTC

Winsten

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

DJ

Lezen

6 mei 2026, 06:19 UTC

Winsten

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

DJ

Lezen

6 mei 2026, 06:13 UTC

Winsten

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

DJ

Lezen

6 mei 2026, 06:13 UTC

Winsten

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

DJ

Lezen

6 mei 2026, 06:12 UTC

Winsten

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

DJ

Lezen

6 mei 2026, 05:43 UTC

Winsten

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

DJ

Lezen

6 mei 2026, 05:42 UTC

Winsten

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

DJ

Lezen

6 mei 2026, 05:40 UTC

Winsten

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

DJ

Lezen

6 mei 2026, 05:40 UTC

Winsten

Novo Nordisk 1Q Op Margin 61.6%

DJ

Lezen

Peer Vergelijking

Prijswijziging

Novo Nordisk A-S (Class B) Prognose

Koersdoel

By TipRanks

9.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,162.73 DKK  9.53%

Hoogste 1,550 DKK

Laagste 720 DKK

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novo Nordisk A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

2

Hold

2

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Novo Nordisk A-S (Class B) - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Andere aandelen uit de sector

GMAB.DK

Genmab A-S

1,683

↓-1.72%

ZEAL.DK

Zealand Pharma A-S

312.39

↓-6.61%

AMBUB.DK

Ambu A-S

62.45

↑ +0.24%
help-icon Live chat